Drug intelligence / Profile preview

TACT411

Development stage: Preclinical
Lead developer: Tactogen
Modality: Small Molecules

Overview

TACT411 is an investigational psychoactive compound classified as a monoamine transporter modulator and serotonin 5-HT1B receptor modulator. It is being developed by Tactogen for the treatment of alcohol use disorder, anorexia, and binge-eating disorder. As of early 2025, it remains in preclinical research. The drug’s mechanism involves modulation of monoamine transporters (which regulate neurotransmitters like serotonin, dopamine, and norepinephrine) as well as direct action on the serotonin 5-HT1B receptor. Its chemical structure has not been publicly disclosed[1].

Targets

MAT (Monoamine transporters)HTR1B (5-Hydroxytryptamine Receptor 1B)

Beyond the preview

Go deeper on TACT411.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TACT411.

Explore the full profile